Prof. Mark L. Tykocinski, M.D. (Chairman)
Professor Tykocinski is the inventor of the DSP technology and a leader in the field of immune regulation. He is Provost of the Thomas Jefferson University in Philadelphia and Dean of the school of medicine. Before joining the Jefferson University, Prof. Tykocinski was Chair of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania for over a decade.
Samir Khleif, M.D.
Director of the GRU Cancer Center and board certified in internal medicine and medical oncology. Served as the Chief of Cancer Vaccine Section at the NCI. He also served as a Special Assistant to the Commissioner of the Food and Drug Administration, leading the Critical Path Initiative for oncology. Dr. Khleif’s research interest is in identifying new and improved strategies to enhance specific immune response against cancer for preventive and therapeutic intent. This is conducted through the understanding of immune regulation and tumor-immune system interaction and translating the findings into therapeutic approaches.
Manuel Hidalgo, M.D., Ph.D
Chief of the Division of Hematology Oncology, Director of the Rosenberg Cancer Center at Beth Israel Deaconess Medical Center and Professor of Medicine at the Harvard Medical School. He is the co-founder and Scientific Advisor of Champions Oncology. His research interest have centered in translational and clinical research in anticancer drug development. His most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalizes medicine in PDAC.
Ezra Cohen, M.D
Ezra Cohen, MD, is co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He recently served as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.
Dr. Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee.